Neuroscience | Penn Today

Microscopic view of Microglia cell and pyramidal neuron.

New approach for brain cell immunotherapy

Penn Medicine researchers have developed a selective medicine to get rid of old microglia, while also replenishing them with transplanted surrogate cells in their place, suggesting future potential for treating and even preventing neurodegenerative disorders.

Health experts want FDA safety review of fast-tracked Alzheimer’s drug

Jason Karlawish of the Perelman School of Medicine says that an independent panel needs to meet to discuss the use of beta amyloid PET scans to support a drug’s accelerated approval.

Human brain organoids transplanted into rats respond to visual stimuli

H. Isaac Chen of the Perelman School of Medicine and colleagues are showing that human organoids implanted into rat visual cortices can respond to flashing visual stimuli.

Human neurons implanted into a rat’s brain respond to flashing lights

Isaac Chen of the Perelman School of Medicine and colleagues found that lab-grown neurons transplanted into rat brains with damaged visual cortexes responded when the rats saw flashing lights.

Two rows of people: William Beltran, Brian Gregory, Insup Lee, Guo-Li Ming. Bottom row: Eric Schelter, Theodore Schurr, Warren Seider, and Karen Winey.

Eight Penn professors elected 2022 AAAS Fellows

Researchers from the School of Arts & Sciences, School of Engineering and Applied Science, Perelman School of Medicine, and School of Veterinary Medicine join a class of scientists, engineers, and innovators spanning 24 scientific disciplines.

Through the lens: A digital depiction of dyslexia

Artist-in-residence and visiting scholar Rebecca Kamen has blended AI and art to produce animated illustrations representing how a dyslexic brain interprets information.

In 30-year study, head injury doubled long-term death risk

A study by Holly Elser of the Perelman School of Medicine and colleagues finds that head injuries may double or even triple the risk of dying early.

Head injury of any kind doubles mortality rate in adults

A study by researchers at the Perelman School of Medicine found that people’s mortality rates from all causes doubled if they had suffered a head injury.

The FDA approved the first Alzheimer’s drug that may really work. A Penn physician explains why you probably can’t get it, yet

David Wolk of the Perelman School of Medicine outlines the key takeaways of new Alzheimer’s drug lecanemab.

New Alzheimer’s drug a ‘breath of life’ for one local family

Jason Karlawish of the Perelman School of Medicine says that patients need mild cognitive impairment or mild-stage dementia to be eligible for new Alzheimer’s drug lecanemab.

Filters